Bronchiectasis: Current Concepts in Pathogenesis, Immunology, and Microbiology.

Bronchiectasis is a disorder of persistent lung inflammation and recurrent infection, defined by a common pathological end point: irreversible bronchial dilatation arrived at through diverse etiologies. This suggests an interplay between immunogenetic susceptibility, immune dysregulation, bacterial infection, and lung damage. The damaged epithelium impairs mucus removal and facilitates bacterial infection with increased cough, sputum production, and airflow obstruction. Lung infection is caused by respiratory bacterial and fungal pathogens, including Pseudomonas aeruginosa, Haemophilus, Aspergillus fumigatus, and nontuberculous mycobacteria. Recent studies have highlighted the relationship between the lung microbiota and microbial-pathogen niches. Disease may result from environments favoring interleukin-17-driven neutrophilia. Bronchiectasis may present in autoimmune disease, as well as conditions of immune dysregulation, such as combined variable immune deficiency, transporter associated with antigen processing-deficiency syndrome, and hyperimmunoglobulin E syndrome. Differences in prevalence across geography and ethnicity implicate an etiological mix of genetics and environment underpinning susceptibility.

[1]  W. Guan,et al.  The Role of Viral Infection in Pulmonary Exacerbations of Bronchiectasis in Adults , 2015, Chest.

[2]  J. Perry,et al.  Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. , 2015, Respiratory medicine.

[3]  I. Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2015, The New England journal of medicine.

[4]  L. Hoffman,et al.  Emerging drugs for bronchiectasis: an update , 2015, Expert opinion on emerging drugs.

[5]  R. Moss Fungi in Cystic Fibrosis and Non–Cystic Fibrosis Bronchiectasis , 2015, Seminars in Respiratory and Critical Care Medicine.

[6]  E. Main,et al.  Airway Clearance Strategies in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis , 2015, Seminars in Respiratory and Critical Care Medicine.

[7]  S. Bell,et al.  Inhaled Antibiotics in Cystic Fibrosis (CF) and Non-CF Bronchiectasis , 2015, Seminars in Respiratory and Critical Care Medicine.

[8]  S. Hasnain,et al.  Adult Non-Cystic Fibrosis Bronchiectasis Is Characterised by Airway Luminal Th17 Pathway Activation , 2015, PloS one.

[9]  J. Chalmers,et al.  Challenges in the development of new therapies for bronchiectasis , 2015, Expert opinion on pharmacotherapy.

[10]  Kathryn J. Quigley,et al.  Chronic Infection by Mucoid Pseudomonas aeruginosa Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F. , 2015, American journal of respiratory and critical care medicine.

[11]  Stefano Aliberti,et al.  Management of bronchiectasis in adults , 2015, European Respiratory Journal.

[12]  T. Murphy Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now , 2015, Clinical and Vaccine Immunology.

[13]  J. Trapani,et al.  Failed CTL/NK cell killing and cytokine hypersecretion are directly linked through prolonged synapse time , 2015, The Journal of experimental medicine.

[14]  Jeffrey L. Curtis,et al.  Analysis of the Upper Respiratory Tract Microbiotas as the Source of the Lung and Gastric Microbiotas in Healthy Individuals , 2015, mBio.

[15]  T. Scriba,et al.  T cells and adaptive immunity to Mycobacterium tuberculosis in humans , 2015, Immunological reviews.

[16]  L. Delhaes,et al.  The lung mycobiome: an emerging field of the human respiratory microbiome , 2015, Front. Microbiol..

[17]  R. Boyton,et al.  Nomenclature: Replace 'pathogens' with 'perceptogens'. , 2015, Nature.

[18]  S. Brix,et al.  Chronic obstructive pulmonary disease and asthma‐associated Proteobacteria, but not commensal Prevotella spp., promote Toll‐like receptor 2‐independent lung inflammation and pathology , 2015, Immunology.

[19]  J. Elborn,et al.  COPD–bronchiectasis overlap syndrome , 2015, European Respiratory Journal.

[20]  M. K. Sidhu,et al.  Developing drug therapies in bronchiectasis , 2015, Expert opinion on investigational drugs.

[21]  A. Chang,et al.  Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease. , 2015, Vaccine.

[22]  P. Taylor,et al.  The biology of IL-23 and IL-17 and their therapeutic targeting in rheumatic diseases , 2015, Current opinion in rheumatology.

[23]  R. Munson,et al.  Overlapping and Complementary Oxidative Stress Defense Mechanisms in Nontypeable Haemophilus influenzae , 2014, Journal of bacteriology.

[24]  M. Daly,et al.  Genetic and Epigenetic Fine-Mapping of Causal Autoimmune Disease Variants , 2014, Nature.

[25]  John R Hurst,et al.  Microbial dysbiosis in bronchiectasis. , 2014, The Lancet. Respiratory medicine.

[26]  D. Bilton,et al.  Non-cystic fibrosis bronchiectasis: an evidence-base for new therapies. , 2014, The Lancet. Respiratory medicine.

[27]  G. Rogers,et al.  The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. , 2014, The Lancet. Respiratory medicine.

[28]  D. Ojcius,et al.  NK cells kill mycobacteria directly by releasing perforin and granulysin , 2014, Journal of leukocyte biology.

[29]  F. Blasi,et al.  COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity? , 2014, COPD.

[30]  D. Denning,et al.  The clinical spectrum of pulmonary aspergillosis , 2014, Thorax.

[31]  E. Génin,et al.  Poor Survival in Rheumatoid Arthritis Associated with Bronchiectasis: A Family-Based Cohort Study , 2014, PloS one.

[32]  D. Leduc,et al.  Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity , 2014, Nature Communications.

[33]  E. Bijnens,et al.  Impact of traffic related air pollution indicators on non-cystic fibrosis bronchiectasis mortality: a cohort analysis , 2014, Respiratory Research.

[34]  Robert E W Hancock,et al.  Host defense peptides: front-line immunomodulators. , 2014, Trends in immunology.

[35]  Haiqing Chu,et al.  Prevalence of nontuberculous mycobacteria in patients with bronchiectasis: a meta-analysis , 2014, Archives of medical science : AMS.

[36]  F. Martinez,et al.  The role of the microbiome in exacerbations of chronic lung diseases , 2014, The Lancet.

[37]  Thomas B. Clarke Early Innate Immunity to Bacterial Infection in the Lung Is Regulated Systemically by the Commensal Microbiota via Nod-Like Receptor Ligands , 2014, Infection and Immunity.

[38]  A. Chang,et al.  Children with Chronic Suppurative Lung Disease Have a Reduced Capacity to Synthesize Interferon-Gamma In Vitro in Response to Non-Typeable Haemophilus influenzae , 2014, PloS one.

[39]  J. Lordan,et al.  Lack of association between KIR and HLA-C type and susceptibility to idiopathic bronchiectasis. , 2014, Respiratory medicine.

[40]  Simon A. Jones,et al.  Ectopic lymphoid-like structures in infection, cancer and autoimmunity , 2014, Nature Reviews Immunology.

[41]  P. Eggleton,et al.  RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients , 2014, European Respiratory Journal.

[42]  C. Huttenhower,et al.  Inflammatory bowel disease as a model for translating the microbiome. , 2014, Immunity.

[43]  E. Giamarellos‐Bourboulis Natural killer cells in sepsis: detrimental role for final outcome. , 2014, Critical care medicine.

[44]  M. McGuckin,et al.  A novel microbiota stratification system predicts future exacerbations in bronchiectasis. , 2014, Annals of the American Thoracic Society.

[45]  I. Masters,et al.  Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children , 2014, Archives of Disease in Childhood.

[46]  Alan W Walker,et al.  Phylogeny, culturing, and metagenomics of the human gut microbiota. , 2014, Trends in microbiology.

[47]  J. Chalmers,et al.  Defining severity in non-cystic fibrosis bronchiectasis , 2014, Expert review of respiratory medicine.

[48]  Stefano Aliberti,et al.  The bronchiectasis severity index. An international derivation and validation study. , 2014, American journal of respiratory and critical care medicine.

[49]  T. Nawrot,et al.  Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. , 2014, Respiratory medicine.

[50]  T. Junt,et al.  Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis , 2014, Nature Medicine.

[51]  J. Faith,et al.  Identifying Gut Microbe–Host Phenotype Relationships Using Combinatorial Communities in Gnotobiotic Mice , 2014, Science Translational Medicine.

[52]  J. Clemente,et al.  Enrichment of Lung Microbiome with Supraglotic Microbes Is Associated with Increased Pulmonary Inflammation , 2014 .

[53]  V. Holers,et al.  When and where does inflammation begin in rheumatoid arthritis? , 2014, Current opinion in rheumatology.

[54]  S. Sørensen,et al.  The murine lung microbiome in relation to the intestinal and vaginal bacterial communities , 2013, BMC Microbiology.

[55]  J. Kolls,et al.  Dysregulation in lung immunity — The protective and pathologic Th17 response in infection , 2013, European journal of immunology.

[56]  Nada Jabado,et al.  Phosphoinositide 3-Kinase δ Gene Mutation Predisposes to Respiratory Infection and Airway Damage , 2013, Science.

[57]  Bihui Huang,et al.  Mucus Enhances Gut Homeostasis and Oral Tolerance by Delivering Immunoregulatory Signals , 2013, Science.

[58]  I. McInnes,et al.  Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. , 2013, Seminars in arthritis and rheumatism.

[59]  J. Norris,et al.  Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. , 2013, Arthritis and rheumatism.

[60]  C. Huttenhower,et al.  Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis , 2013, eLife.

[61]  Mark S. Sundrud,et al.  T Cell–Derived IL-17 Mediates Epithelial Changes in the Airway and Drives Pulmonary Neutrophilia , 2013, The Journal of Immunology.

[62]  Edward T Naureckas,et al.  Non-cystic fibrosis bronchiectasis. , 2013, American journal of respiratory and critical care medicine.

[63]  J. Orange Natural killer cell deficiency. , 2013, The Journal of allergy and clinical immunology.

[64]  Darren L. Smith,et al.  Polymicrobial airway bacterial communities in adult bronchiectasis patients , 2013, BMC Microbiology.

[65]  A. Hill,et al.  Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. , 2013, Molecular immunology.

[66]  T. Welte,et al.  Bronchiectasis-Associated Hospitalizations in Germany, 2005–2011: A Population-Based Study of Disease Burden and Trends , 2013, PloS one.

[67]  M. Hattori,et al.  Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota , 2013, Nature.

[68]  B. B. Finlay,et al.  The role of the immune system in governing host-microbe interactions in the intestine , 2013, Nature Immunology.

[69]  Richard C Boucher,et al.  Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. , 2013, American journal of respiratory and critical care medicine.

[70]  Emily S. Charlson,et al.  Widespread colonization of the lung by Tropheryma whipplei in HIV infection. , 2013, American journal of respiratory and critical care medicine.

[71]  G. Rogers,et al.  Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition , 2013, Thorax.

[72]  Robert E W Hancock,et al.  Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. , 2013, Pathogens and disease.

[73]  A. Condliffe,et al.  Coexistence of Bronchiectasis and Rheumatoid Arthritis: Revisited , 2013, Respiratory Care.

[74]  M. McGuckin,et al.  Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. , 2013, JAMA.

[75]  W. Boersma,et al.  Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. , 2013, JAMA.

[76]  C. Akdis,et al.  A Th17- and Th2-skewed cytokine profile in cystic fibrosis lungs represents a potential risk factor for Pseudomonas aeruginosa infection. , 2013, American journal of respiratory and critical care medicine.

[77]  Kathryn J. Quigley,et al.  Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis , 2013, Clinical and experimental immunology.

[78]  C. Olveira,et al.  Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score , 2012, European Respiratory Journal.

[79]  S. Homma,et al.  Pulmonary involvement in ANCA-associated vasculitis from the view of the pulmonologist , 2013, Clinical and Experimental Nephrology.

[80]  Jeremy S. Brown,et al.  Research priorities in bronchiectasis , 2012, Thorax.

[81]  A. Hill,et al.  Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. , 2012, American journal of respiratory and critical care medicine.

[82]  D. Altmann,et al.  Immune regulation in idiopathic bronchiectasis , 2012, Annals of the New York Academy of Sciences.

[83]  S. Lory,et al.  Transcriptional Response of Mucoid Pseudomonas aeruginosa to Human Respiratory Mucus , 2012, mBio.

[84]  M. Sugimoto,et al.  Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. , 2012, Respiratory medicine.

[85]  A. Hill,et al.  Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis , 2012, Thorax.

[86]  A. Viale,et al.  Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. , 2012, Arthritis and rheumatism.

[87]  Taane G. Clark,et al.  Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice , 2012, PLoS pathogens.

[88]  Timothy L. Tickle,et al.  Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment , 2012, Genome Biology.

[89]  N. Karalus,et al.  Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.

[90]  S. Welham,et al.  British Thoracic Society national bronchiectasis audit 2010 and 2011 , 2012, Thorax.

[91]  M. Strek,et al.  Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. , 2012, Chest.

[92]  Curtis Huttenhower,et al.  Microbial Co-occurrence Relationships in the Human Microbiome , 2012, PLoS Comput. Biol..

[93]  D. Griffith,et al.  Bronchiectasis and nontuberculous mycobacterial disease. , 2012, Clinics in chest medicine.

[94]  D. Lynch,et al.  Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? , 2012, Arthritis and rheumatism.

[95]  Bernard Henrissat,et al.  Metabolic Reconstruction for Metagenomic Data and Its Application to the Human Microbiome , 2012, PLoS Comput. Biol..

[96]  Katherine H. Huang,et al.  Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.

[97]  A. Chang,et al.  Culture and PCR Detection of Haemophilus influenzae and Haemophilus haemolyticus in Australian Indigenous Children with Bronchiectasis , 2012, Journal of Clinical Microbiology.

[98]  M. Blaser,et al.  The human microbiome: at the interface of health and disease , 2012, Nature Reviews Genetics.

[99]  M. Hewison An update on vitamin D and human immunity , 2012, Clinical endocrinology.

[100]  A. El Maghraoui,et al.  Prevalence and Characteristics of Lung Involvement on High Resolution Computed Tomography in Patients with Ankylosing Spondylitis: A Systematic Review , 2012, Pulmonary medicine.

[101]  S. Holland,et al.  Trends in bronchiectasis among medicare beneficiaries in the United States, 2000 to 2007. , 2011, Chest.

[102]  Jenna M. Sullivan,et al.  Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. , 2011, Immunity.

[103]  C. Jimenez,et al.  Thoracic manifestations of inflammatory bowel disease. , 2011, AJR. American journal of roentgenology.

[104]  A. Bush,et al.  The Th17 pathway in cystic fibrosis lung disease. , 2011, American journal of respiratory and critical care medicine.

[105]  J. Kolls,et al.  The development of inducible Bronchus Associated Lymphoid Tissue (iBALT) is dependent on IL-17 , 2011, Nature Immunology.

[106]  John D. Mitchell,et al.  Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[107]  J. Maurer Trends and Burden of Bronchiectasis-Associated Hospitalizations in the United States, 1993-2006 , 2011 .

[108]  J. DiNicolantonio,et al.  Azithromycin for prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[109]  T. Murphy,et al.  Characterization and Evaluation of the Moraxella catarrhalis Oligopeptide Permease A as a Mucosal Vaccine Antigen , 2010, Infection and Immunity.

[110]  P. Morris,et al.  Respiratory bacterial pathogens in the nasopharynx and lower airways of Australian indigenous children with bronchiectasis. , 2010, The Journal of pediatrics.

[111]  J. Sohn,et al.  High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. , 2010, The Tohoku journal of experimental medicine.

[112]  R. Wait,et al.  Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[113]  M. Ramos-Casals,et al.  Bronchiectasis in primary Sjögren's syndrome: prevalence and clinical significance. , 2010, Clinical and experimental rheumatology.

[114]  M. Givskov,et al.  The immune system vs. Pseudomonas aeruginosa biofilms. , 2010, FEMS immunology and medical microbiology.

[115]  R. Hubbard,et al.  Trends in bronchiectasis mortality in England and Wales. , 2010, Respiratory medicine.

[116]  D Bilton,et al.  British Thoracic Society guideline for non-CF bronchiectasis , 2010, Thorax.

[117]  Eoin L. Brodie,et al.  Airway Microbiota and Pathogen Abundance in Age-Stratified Cystic Fibrosis Patients , 2010, PloS one.

[118]  S. Holland,et al.  Chronic granulomatous disease. , 2010, Inflammatory bowel diseases.

[119]  Dan R. Littman,et al.  Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria , 2009, Cell.

[120]  E. Bergseng,et al.  Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation , 2009, Nature Immunology.

[121]  K. Mathee,et al.  Comparative transcriptome analyses of Pseudomonas aeruginosa , 2009, Human Genomics.

[122]  D. Hansell,et al.  Mortality in bronchiectasis: a long-term study assessing the factors influencing survival , 2009, European Respiratory Journal.

[123]  A. Blom,et al.  Interpain A, a Cysteine Proteinase from Prevotella intermedia, Inhibits Complement by Degrading Complement Factor C3 , 2009, PLoS pathogens.

[124]  R. Boyton Regulation of immunity in bronchiectasis. , 2009, Medical mycology.

[125]  S. Holland,et al.  Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3 , 2008, Current opinion in allergy and clinical immunology.

[126]  D. Hassett,et al.  NKG2D Is Critical for NK Cell Activation in Host Defense against Pseudomonas aeruginosa Respiratory Infection1 , 2008, The Journal of Immunology.

[127]  P. Hutchinson,et al.  Cytotoxic T lymphocyte and natural killer cell responses to non‐typeable Haemophilus influenzae , 2008, Clinical and experimental immunology.

[128]  M. Wolfgang,et al.  Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. , 2008, American journal of respiratory and critical care medicine.

[129]  D. Altmann,et al.  Human leucocyte antigen class II association in idiopathic bronchiectasis, a disease of chronic lung infection, implicates a role for adaptive immunity , 2008, Clinical and experimental immunology.

[130]  G. Pier,et al.  Vaccines and immunotherapy against Pseudomonas aeruginosa. , 2008, Vaccine.

[131]  F. Lazzarotto,et al.  Sicilian family with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and lethal lung disease in one of the affected brothers , 2008, European Journal of Pediatrics.

[132]  S. Fuschillo,et al.  Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms , 2008, European Respiratory Journal.

[133]  Atlanta,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. , 2008, Arthritis and rheumatism.

[134]  J. Soriano,et al.  Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. , 2007, Chest.

[135]  R. Knight,et al.  The Human Microbiome Project , 2007, Nature.

[136]  S. Miyazaki,et al.  Gr-1high Polymorphonuclear Leukocytes and NK Cells Act via IL-15 to Clear Intracellular Haemophilus influenzae in Experimental Murine Peritonitis and Pneumonia1 , 2007, The Journal of Immunology.

[137]  P. King,et al.  Microbiologic follow-up study in adult bronchiectasis. , 2007, Respiratory medicine.

[138]  D. Altmann,et al.  Natural killer cells, killer immunoglobulin‐like receptors and human leucocyte antigen class I in disease , 2007, Clinical and experimental immunology.

[139]  G. Karabıyıkoğlu,et al.  Analysis of the factors related to mortality in patients with bronchiectasis. , 2007, Respiratory medicine.

[140]  C. Meisner,et al.  A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients , 2007, Proceedings of the National Academy of Sciences.

[141]  R. Moots,et al.  Haemophilus influenzae induces neutrophil necrosis: a role in chronic obstructive pulmonary disease? , 2007, American journal of respiratory cell and molecular biology.

[142]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.

[143]  Mary Carrington,et al.  KIR and disease: a model system or system of models? , 2006, Immunological reviews.

[144]  M. Gaxiola,et al.  Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. , 2006, The Journal of clinical investigation.

[145]  R. Wilson,et al.  The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis , 2006, European Respiratory Journal.

[146]  D. Jewell,et al.  IFN gamma and CXCR-1 gene polymorphisms in idiopathic bronchiectasis. , 2006, Tissue antigens.

[147]  R. Wilson,et al.  Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis , 2006, European Respiratory Journal.

[148]  P. Hutchinson,et al.  Assessing immune function in adult bronchiectasis , 2006, Clinical and experimental immunology.

[149]  R. De Wit,et al.  'Everything is everywhere, but, the environment selects'; what did Baas Becking and Beijerinck really say? , 2006, Environmental microbiology.

[150]  J. Trowsdale,et al.  HLA-C and killer cell immunoglobulin-like receptor genes in idiopathic bronchiectasis. , 2006, American journal of respiratory and critical care medicine.

[151]  B. Grant,et al.  Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. , 2005, American journal of respiratory and critical care medicine.

[152]  C. Byrnes,et al.  New Zealand national incidence of bronchiectasis “too high” for a developed country , 2005, Archives of Disease in Childhood.

[153]  M. Newport,et al.  Clinical features of dominant and recessive interferon γ receptor 1 deficiencies , 2004, The Lancet.

[154]  M. Tabrizi,et al.  Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. , 2004, Chest.

[155]  Clare Baecher-Allan,et al.  Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis , 2004, The Journal of experimental medicine.

[156]  M. Ennis,et al.  Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis , 2004, Thorax.

[157]  P. Hutchinson,et al.  Adaptive immunity to nontypeable Haemophilus influenzae. , 2003, American journal of respiratory and critical care medicine.

[158]  A. Chang,et al.  Bronchiectasis in Indigenous children in remote Australian communities , 2002, The Medical journal of Australia.

[159]  Richard C Boucher,et al.  Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. , 2002, The Journal of clinical investigation.

[160]  R. Rodríguez-Roisín,et al.  Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors , 2002, Thorax.

[161]  I. Brook Anaerobic infections in children. , 1986, Microbes and infection.

[162]  A. Andonopoulos,et al.  Bronchiectasis in systemic sclerosis. A study using high resolution computed tomography. , 2001, Clinical and experimental rheumatology.

[163]  M. Keogan,et al.  An investigation into causative factors in patients with bronchiectasis. , 2000, American journal of respiratory and critical care medicine.

[164]  J. Trowsdale,et al.  TAP deficiency syndrome , 2000, Clinical and experimental immunology.

[165]  G. Redding,et al.  Bronchiectasis in Alaska Native children: Causes and clinical courses , 2000 .

[166]  G. Ooi,et al.  Sputum elastase in steady-state bronchiectasis. , 2000, Chest.

[167]  L. Sollid Molecular basis of celiac disease. , 2000, Annual review of immunology.

[168]  S. Durham,et al.  Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis , 1998, Thorax.

[169]  J. Shneerson,et al.  Bronchiectasis in association with coeliac disease , 1998, Thorax.

[170]  A. Wells,et al.  Bronchiectasis following colectomy for Crohn’s disease , 1998, Thorax.

[171]  R. Stockley,et al.  IgG subclasses in the serum and sputum from patients with bronchiectasis , 1998, Thorax.

[172]  R. Stockley Commentary: bronchiectasis and inflammatory bowel disease , 1998, Thorax.

[173]  V. Devauchelle,et al.  Prevalence of symptomatic bronchiectasis in patients with rheumatoid arthritis. , 1997, Revue du rhumatisme.

[174]  P. Jones,et al.  Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. , 1997, The European respiratory journal.

[175]  D. Hansell,et al.  Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. , 1997, Thorax.

[176]  D. Wendling,et al.  Bronchectasies et polyarthrite rhumatoïde. Fréquence et aspects étiopathogéniques. Revue de la littérature , 1997 .

[177]  D. Wendling,et al.  [Bronchiectasis and rheumatoid arthritis. Incidence and etiopathogenic aspects. Review of the literature]. , 1997, La Revue de medecine interne.

[178]  H. Fenlon,et al.  High-resolution chest CT in systemic lupus erythematosus. , 1996, AJR. American journal of roentgenology.

[179]  M. Miravitlles,et al.  IgG subclass deficiencies associated with bronchiectasis. , 1996, American journal of respiratory and critical care medicine.

[180]  M. Suarez‐Almazor,et al.  HLA-DR1, DR4, and DRB1 disease related subtypes in rheumatoid arthritis. Association with susceptibility but not severity in a city wide community based study. , 1995, The Journal of rheumatology.

[181]  H. Lode,et al.  Cells and Cytokines in Chronic Bronchial Infection , 1994, Annals of the New York Academy of Sciences.

[182]  L. Young,et al.  Mycobacterial diseases and the compromised host. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[183]  P. Cole,et al.  The immunological component of the cellular inflammatory infiltrate in bronchiectasis. , 1989, Thorax.

[184]  P. Cole,et al.  Host-microbe relationships in chronic respiratory infection. , 1989, Respiration; international review of thoracic diseases.

[185]  P. Cole,et al.  INDIUM-111-LABELLED GRANULOCYTE ACCUMULATION IN RESPIRATORY TRACT OF PATIENTS WITH BRONCHIECTASIS , 1987, The Lancet.

[186]  Coletsos Pj Inflammation: a two-edged sword--the model of bronchiectasis. , 1986 .

[187]  M. Turner-Warwick,et al.  The British Thoracic Society. , 1982, Thorax.

[188]  R. J. Butland,et al.  Chronic bronchial suppuration and inflammatory bowel disease. , 1981, The Quarterly journal of medicine.

[189]  L. Doyle,et al.  Immunological abnormalities in bronchiectasis with chronic bronchial suppuration. , 1978, British journal of diseases of the chest.

[190]  J. L. Potter,et al.  Studies on pulmonary secretions. II. Osmolality and the ionic environment of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. , 1967, The American review of respiratory disease.

[191]  E. Bywaters,et al.  Lung Lesions in Rheumatoid Arthritis , 1955, British medical journal.

[192]  N. Wynn-Williams Bronchiectasis: A Study Centred on Bedford and Its Environs* , 1953, British medical journal.

[193]  F. Whitwell A Study of the Pathology and Pathogenesis of Bronchiectasis * , 1952, Thorax.

[194]  The Child's Lung , 1948 .

[195]  J. C. Hoyle,et al.  Observations on DRY BRONCHIECTASIS , 1933, British medical journal.